Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2022 / Cilt: 19 - Sayı: 1

Importance of endometrial biopsy in premenopausal women without risk factors for endometrial cancer

Endometriyum kanseri için risk faktörü olmayan premenopozal kadınlarda endometriyal biyopsinin önemi

Pages
1142–1145
Publication Date
2022-03-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Endometrial biopsy indications should be reviewed in this patient group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In women with abnormal uterine bleeding, the appropriate age for endometrial biopsy remains controversial.
📊
Key Findings & Data:In this study, we aimed to evaluate the importance of endometrial biopsy in premenopausal women aged 40-49 years who presented with menorrhagia but did not have risk factors for endometrial cancer.
💡
Conclusion & Impact:Endometrial biopsy indications should be reviewed in this patient group.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Endometrial biyopsi · endometrium kanseri · menoraji

Abstract

Objective: In women with abnormal uterine bleeding, the appropriate age for endometrial biopsy remains controversial. In this study, we aimed to evaluate the importance of endometrial biopsy in premenopausal women aged 40-49 years who presented with menorrhagia but did not have risk factors for endometrial cancer. Material And Methods: The records of patients who underwent endometrial biopsy for diagnostic purposes at the gynecology and obstetrics clinic of our hospital between January 1, 2017 and October 31, 2021 were retrospectively reviewed. Among these patients, premenopausal women aged 40-49 years with menorrhagia who had endometrial biopsy results were included in the sample. Patients with risk factors were excluded from the study. Results: A total of 176 premenopausal patients with menorrhagia were included in the study. According to the biopsy results of these patients without risk factors, no malignancy was detected. Endometrial hyperplasia was present in six patients (3.4%), of whom (0.6%) had hyperplasia with atypia and five (2.8%) had hyperplasia without atypia. Conclusion: We found a minimal risk of neoplastic and preneoplastic disease in premenopausal women aged 40-49 years with menorrhagia but no risk factors for endometrial cancer. Endometrial biopsy indications should be reviewed in this patient group.

Özet

Amaç: Anormal uterin kanaması olan kadınlarda endometrial biyopsi için uygun yaş tartışmalıdır. Bu çalışmada endometriyum kanser için risk faktörü olmayan ve menorajisi olan 40-49 yaş arası premenopozal kadınlarda endometriyal biyopsinin önemini değerlendirmeyi amaçladık. Gereçler ve Yöntem: 1 Ocak 2017-31 Ekim 2021 tarihleri arasında hastanemizin Kadın Hastalıkları ve Doğum kliniğinde diagnostik amaçlı endometrial biyopsi yapılan hastaların kayıtları retrospektif olarak incelendi. Bu hastalardan endometrial biyopsi sonuçları olan menorajili 40-49 yaş arası premenopozal kadınlar çalışmaya dahil edildi. Risk faktörü olan hastalar çalışma dışı bırakıldı. Bulgular: Çalışmaya, menorajisi olan 176 premenopozal hasta dahil edildi. Risk faktörleri olmayan hastaların biyopsi sonuçlarında malignite saptanmadı. Toplam 6 olguda endometrial hiperplazi (EH) (%3.4) saptandı. EH saptanan olguların 1’i (%0.6) atipili hiperplazi, 5’i (%2.8) atipisiz hiperplazi olarak saptandı. Sonuç: Risk faktörleri olmayan ve menorajisi olan 40-49 yaş arası premenopozal kadınlarda neoplastik ve preneoplastik hastalık riskini minimal olarak tespit ettik. Bu hasta grubunda endometriyal biyopsi endikasyonları gözden geçirilmelidir.

🔖

Cite This Article

SERT, Z. S. (2022). Importance of endometrial biopsy in premenopausal women without risk factors for endometrial cancer. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 19 - Sayı: 1, 1142–1145. https://ajindex.com/articles/676524

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
  2. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi33–8
  3. McKenney JK, Longacre TA. Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol 2009. 16(1): p. 1-22
  4. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009. 113(1): p. 105-8
  5. Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 2017;124(3):404-411
  6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–86
  7. Wise MR, Gill P, Lensen S, Thompson JM, Farquhar CM. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol 2016; 215:598.e1-8
  8. Giannella L, Cerami LB, Setti T, Bergamini E, Boselli F. Prediction of endometrial hyperplasia and cancer among premenopausal women with abnormal uterine bleeding. Biomed Res Int 2019; 2019:8598152
  9. American Joint Committee on Cancer. Corpus Uteri. In Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, (eds). AJCC Staging Manual, 7th. edition. New York. Springer. 2010. p. 403
  10. Aker SŞ, Yüce T, Acar D, Atabekoğlu CS. Anormal Uterin Kanaması olan Kadınlarda Endometrial Örnekleme Sonuçları: 765 Vakanın Retrospektif Analizi. Cukurova Medical Journal 2015;40:306-10
  11. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17(3):216- 222
  12. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin 2014; 64(1): 9-29
  13. ACOG Committee on Practice Bulletins Gynecology. Practice bulletin no. 136: Management Of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol 2013;122(1):176- 85
  14. Murray M.J., Meyer W.R., Zaino R.J.